Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,267 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pharmacokinetics of etoricoxib in patients with hepatic impairment.
Agrawal NG, Rose MJ, Matthews CZ, Woolf EJ, Porras AG, Geer LA, Larson PJ, Cote J, Dilzer SC, Lasseter KC, Alam I, Petty KJ, Gottesdiener KM. Agrawal NG, et al. Among authors: cote j. J Clin Pharmacol. 2003 Oct;43(10):1136-48. doi: 10.1177/0091270003257219. J Clin Pharmacol. 2003. PMID: 14517196 Clinical Trial.
Pharmacokinetics of etoricoxib in patients with renal impairment.
Agrawal NG, Matthews CZ, Mazenko RS, Kline WF, Woolf EJ, Porras AG, Geer LA, Wong PH, Cho M, Cote J, Marbury TC, Moncrief JW, Alcorn H Jr, Swan S, Sack MR, Robson RA, Petty KJ, Schwartz JI, Gottesdiener KM. Agrawal NG, et al. Among authors: cote j. J Clin Pharmacol. 2004 Jan;44(1):48-58. doi: 10.1177/0091270003260338. J Clin Pharmacol. 2004. PMID: 14681341
Safety, tolerability, pharmacokinetics, and pharmacodynamic properties of taranabant, a novel selective cannabinoid-1 receptor inverse agonist, for the treatment of obesity: results from a double-blind, placebo-controlled, single oral dose study in healthy volunteers.
Addy C, Li S, Agrawal N, Stone J, Majumdar A, Zhong L, Li H, Yuan J, Maes A, Rothenberg P, Cote J, Rosko K, Cummings C, Warrington S, Boyce M, Gottesdiener K, Stoch A, Wagner J. Addy C, et al. Among authors: cote j. J Clin Pharmacol. 2008 Apr;48(4):418-27. doi: 10.1177/0091270008314467. Epub 2008 Feb 7. J Clin Pharmacol. 2008. PMID: 18258750 Clinical Trial.
Multiple-dose pharmacokinetics, pharmacodynamics, and safety of taranabant, a novel selective cannabinoid-1 receptor inverse agonist, in healthy male volunteers.
Addy C, Rothenberg P, Li S, Majumdar A, Agrawal N, Li H, Zhong L, Yuan J, Maes A, Dunbar S, Cote J, Rosko K, Van Dyck K, De Lepeleire I, de Hoon J, Van Hecken A, Depré M, Knops A, Gottesdiener K, Stoch A, Wagner J. Addy C, et al. Among authors: cote j. J Clin Pharmacol. 2008 Jun;48(6):734-44. doi: 10.1177/0091270008317591. J Clin Pharmacol. 2008. PMID: 18508950 Clinical Trial.
Influence of renal and hepatic impairment on the pharmacokinetics of anacetrapib.
Lauring B, Li XS, Liu Y, Corr C, Lazarus N, Cote J, Larson P, Levonas AO, Lasseter KC, Preston RA, Smith WB, Lai E, Wagner JA. Lauring B, et al. Among authors: cote j. J Clin Pharmacol. 2014 Nov;54(11):1247-55. doi: 10.1002/jcph.320. Epub 2014 Jun 6. J Clin Pharmacol. 2014. PMID: 24782116 Clinical Trial.
Single-dose pharmacokinetics and pharmacodynamics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects.
Krishna R, Garg A, Panebianco D, Cote J, Bergman AJ, Van Hoydonck P, Laethem T, Van Dyck K, Chen J, Chavez-Eng C, Archer L, Lutz R, Hilliard D, Snyder K, Jin B, Van Bortel L, Lasseter KC, Al-Huniti N, Dykstra K, Gottesdiener K, Wagner JA. Krishna R, et al. Among authors: cote j. Br J Clin Pharmacol. 2009 Oct;68(4):535-45. doi: 10.1111/j.1365-2125.2009.03465.x. Br J Clin Pharmacol. 2009. PMID: 19843057 Free PMC article. Clinical Trial.
Multiple-dose pharmacodynamics and pharmacokinetics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects.
Krishna R, Bergman AJ, Jin B, Fallon M, Cote J, Van Hoydonck P, Laethem T, Gendrano IN 3rd, Van Dyck K, Hilliard D, Laterza O, Snyder K, Chavez-Eng C, Lutz R, Chen J, Bloomfield DM, De Smet M, Van Bortel LM, Gutierrez M, Al-Huniti N, Dykstra K, Gottesdiener KM, Wagner JA. Krishna R, et al. Among authors: cote j. Clin Pharmacol Ther. 2008 Dec;84(6):679-83. doi: 10.1038/clpt.2008.109. Epub 2008 Jun 25. Clin Pharmacol Ther. 2008. PMID: 18580870 Clinical Trial. No abstract available.
Laropiprant in combination with extended-release niacin does not alter urine 11-dehydrothromboxane B2, a marker of in vivo platelet function, in healthy, hypercholesterolemic, and diabetic subjects.
Lauring B, Dishy V, Luo WL, Laterza O, Patterson J, Cote J, Chao A, Larson P, Gutierrez M, Wagner JA, Lai E. Lauring B, et al. Among authors: cote j. J Clin Pharmacol. 2009 Dec;49(12):1426-35. doi: 10.1177/0091270009339593. Epub 2009 Oct 15. J Clin Pharmacol. 2009. PMID: 19833861 Clinical Trial.
1,267 results